Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (stock symbol: REVB) is a clinical-stage life sciences company dedicated to advancing immunologic therapeutics and diagnostics designed to improve global health. At the core of its innovative endeavors is Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established TLR4 agonist. This formulation is designed to stimulate the body's innate immune response to prevent and treat various diseases.
The company is actively developing a pipeline of high-value product candidates based on this unique Gemini formulation. These programs include:
- Gemini-SSI: Focused on preventing surgical site infections (SSI).
- Gemini-AKI: Aimed at preventing acute kidney injury (AKI).
- Gemini-CKD: Targeted at treating chronic kidney disease (CKD).
Revelation Biosciences, Inc. is committed to leveraging the science of trained immunity through the Gemini-based products to address significant unmet medical needs and improve patient outcomes. The company continues to make strides in their clinical trials and research, aiming for groundbreaking advancements in healthcare.
With a strong focus on innovation and a dedication to enhancing patient health, Revelation Biosciences, Inc. stands as a significant player in the biotech industry, promising solutions to some of the most challenging health conditions.
Rhea-AI Summary
Revelation Biosciences, Inc. (REVB) reports financial results for the three and twelve months ended December 31, 2023. The company completed a $6.2 million public offering and initiated a Phase 1 clinical study of Gemini. Positive nonclinical data on Gemini's impact on acute kidney injury was presented at a conference. Revelation had $12.0 million in cash and cash equivalents as of December 31, 2023, compared to $5.3 million in 2022. The net loss for the three months ended December 31, 2023, was $2.2 million, with a basic and diluted net loss per share of $8.33, while the net loss for the twelve months ended December 31, 2023, was $0.1 million, with a basic and diluted net loss per share of $0.53.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announces positive preclinical data on Gemini's potential therapeutic benefits for acute kidney injury. Results show significant improvements in kidney function, reduced tissue damage, and inflammation markers. The company is optimistic about Gemini's ability to treat inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) CEO, James Rolke, to participate in a virtual fireside chat at the 36th Annual Roth Conference. The event will take place on March 17-19, 2023, at The Ritz Carlton, Laguna Niguel, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) initiates Phase 1 clinical study for Gemini, a TLR4 agonist, to prevent acute kidney injury and post-surgical infections. Top-line data on safety, tolerability, and biomarker activity expected this summer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) will present new preclinical data on Gemini, a potential therapy for acute kidney injury, at The 29th International Conference on Advances in Critical Care Nephrology. The company aims to address the unmet medical need for AKI prevention and hospital-acquired infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. announced the closing of a public offering, raising approximately $6.2 million. The company plans to use the net proceeds for the development of various clinical studies and products, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announced the pricing of a public offering of 1,365,000 shares of its common stock, along with warrants to purchase up to 2,730,000 shares at an offering price of $4.53 per share. The closing of the offering is expected to occur on or around April 6, 2021. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-63.86%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announced the presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) at an upcoming conference. The data will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) in San Diego. Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection. The presentation will be made by Robin Marsden, Senior Vice President of Biology, Revelation Biosciences. The CEO, James Rolke, expressed excitement about the opportunity to share their preclinical data for the prevention of AKI at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.8%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) has announced a 1-for-30 reverse stock split of its common stock, effective January 25, 2024, to increase the market price per share and regain compliance with Nasdaq listing requirements. The reverse stock split will affect all stockholders uniformly, with adjustments to warrants, restricted stock unit awards, and stock options. The CUSIP number for the common stock will change to 76135L507 post-split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
Rhea-AI Summary
Revelation Biosciences, Inc. (NASDAQ: REVB) reported its financial results for the three and nine months ended September 30, 2023. The company highlighted recent biomarker data showing the pharmacologic activity of Gemini in preclinical studies, presented at a healthcare conference, and announced the upcoming start of a Phase 1 clinical study. Financially, Revelation had $14.0 million in cash and cash equivalents as of September 30, 2023, with sufficient funds to support operations through September 2024. The net loss for the three months ended September 30, 2023, was $2.6 million, while the net income for the nine months ended September 30, 2023, was $2.1 million, primarily due to the change in fair value of the warrant liability creating an $8.3 million gain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
The current stock price of Revelation Biosciences (REVB) is $0.3005 as of December 24, 2024.
What is the market cap of Revelation Biosciences (REVB)?
The market cap of Revelation Biosciences (REVB) is approximately 2.5M.
What is Revelation Biosciences, Inc.?
Revelation Biosciences, Inc. is a clinical-stage life sciences company that develops immunologic therapeutics and diagnostics aimed at improving global health.
What is the core technology of Revelation Biosciences, Inc.?
The core technology is Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), which stimulates the body's innate immune response.
What are the primary programs based on the Gemini formulation?
The primary programs include Gemini-SSI for preventing surgical site infections, Gemini-AKI for preventing acute kidney injury, and Gemini-CKD for treating chronic kidney disease.
What is the stock symbol for Revelation Biosciences, Inc.?
The stock symbol for Revelation Biosciences, Inc. is REVB.
What diseases are targeted by Revelation Biosciences, Inc. products?
The products target diseases such as surgical site infection, acute kidney injury, and chronic kidney disease.
How does the Gemini formulation work?
Gemini works by using PHAD, a TLR4 agonist, to stimulate the body's innate immune response to prevent and treat diseases.
Is Revelation Biosciences, Inc. conducting clinical trials?
Yes, Revelation Biosciences, Inc. is actively conducting clinical trials and research to advance their product candidates.
What is the goal of Revelation Biosciences, Inc.?
The goal is to leverage the science of trained immunity to address significant unmet medical needs and improve patient outcomes.
Where can I find the latest news about Revelation Biosciences, Inc.?
The latest news can be found on their official website and financial news platforms like StockTitan.
What makes Revelation Biosciences, Inc. unique in the biotech industry?
Their unique approach using the Gemini formulation to stimulate innate immune responses sets them apart in developing innovative therapies for disease prevention and treatment.
Revelation Biosciences, Inc.
Nasdaq:REVB
REVB Rankings
REVB Stock Data
2.51M
4.29M
0.12%
2.31%
9.98%
Biotechnology
Pharmaceutical Preparations
United States of America
SAN DIEGO